Academic Journal
Inflammatory memory as a potential driver of rosacea pathogenesis: integrating mechanisms of chronic relapse and perspectives on disease modification.
| Τίτλος: | Inflammatory memory as a potential driver of rosacea pathogenesis: integrating mechanisms of chronic relapse and perspectives on disease modification. |
|---|---|
| Συγγραφείς: | Zhang M; Department of Dermatology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China., Zhou Z; Department of Dermatology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China., Zhan D; Department of Dermatology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China., Yang Y; Department of Dermatology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China., Li M; Department of Dermatology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2026 Sep 30; Vol. 17, pp. 1962766. Date of Electronic Publication: 2026 Sep 30 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | Rosacea*/immunology , Rosacea*/etiology , Rosacea*/pathology , Rosacea*/therapy , Inflammation*/immunology , Memory T Cells*/immunology , Immunologic Memory*, Humans ; Recurrence ; Animals ; Trained Immunity ; Chronic Disease |
| Περίληψη: | Inflammatory memory refers to functional changes retained by a tissue after an inflammatory episode that allow faster or stronger responses to subsequent challenges. It encompasses epigenetic memory in epithelial and stem cells, trained immunity, and tissue-resident memory T cells. Rosacea is a chronic inflammatory skin disease characterized by recurrent flushing, persistent erythema, and papulopustular lesions, and relapse after treatment cessation is common; the mechanisms that drive recurrence remain unclear. In this hypothesis-generating critical review, we use inflammatory memory as an integrative framework and examine evidence consistent with inflammatory memory in rosacea, including the Toll-like receptor 2/kallikrein-related peptidase 5/cathelicidin antimicrobial peptide (LL-37) positive feedback axis, mast-cell-mediated amplification, neuroimmune amplification, and an interleukin-1β-centered persistent inflammatory program. We draw on mechanistic evidence from psoriasis and atopic dermatitis related to tissue-resident memory T cells, epithelial memory, and trained immunity, while explicitly separating established rosacea-specific observations from indirect cross-disease parallels and speculative claims. A multilayer memory network model is proposed in which repeated triggers write memory and lower the relapse threshold; disease modification is then discussed as a candidate therapeutic goal, together with potential strategies and testable hypotheses. Direct molecular evidence for inflammatory memory in rosacea is still lacking, alternative mechanisms remain plausible, and disease modification should be viewed as a perspective rather than an established endpoint. (Copyright © 2026 Zhang, Zhou, Zhan, Yang and Li.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | J Am Acad Dermatol. 2013 Oct;69(4):570-7. (PMID: 23871720) J Allergy Clin Immunol. 2023 Jul;152(1):126-135. (PMID: 36963619) JID Innov. 2024 Mar 22;4(3):100277. (PMID: 38708420) J Am Acad Dermatol. 2026 Jul 24;:. (PMID: 42497917) J Am Acad Dermatol. 2026 Jan;94(1):66-72. (PMID: 40825395) J Eur Acad Dermatol Venereol. 2023 Apr;37(4):796-809. (PMID: 36367676) J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2589-2600. (PMID: 37606610) Dermatol Pract Concept. 2022 Oct 01;12(4):e2022201. (PMID: 36534532) J Dtsch Dermatol Ges. 2022 Aug;20(8):1147-1165. (PMID: 35929658) Science. 2016 Apr 22;352(6284):aaf1098. (PMID: 27102489) J Invest Dermatol. 2012 May;132(5):1435-42. (PMID: 22336948) Lancet. 2023 Jan 21;401(10372):204-214. (PMID: 36509097) Br J Dermatol. 2019 Jul;181(1):65-79. (PMID: 30585305) J Invest Dermatol. 2018 Aug;138(8):1754-1763. (PMID: 29510191) Nature. 2018 Aug;560(7720):649-654. (PMID: 30135581) Dermatol Ther. 2022 Jan;35(1):e15180. (PMID: 34713539) Br J Dermatol. 2020 Nov;183(5):942-943. (PMID: 32364247) Ann Allergy Asthma Immunol. 2025 Feb;134(2):144-150. (PMID: 39383939) Exp Ther Med. 2020 Jun;19(6):3543-3550. (PMID: 32346416) Ann Dermatol. 2022 Dec;34(6):451-460. (PMID: 36478427) J Invest Dermatol. 2014 Apr;134(4):1143-1145. (PMID: 24213369) Front Immunol. 2025 Nov 26;16:1672021. (PMID: 41383625) J Eur Acad Dermatol Venereol. 2016 May;30(5):829-36. (PMID: 26691278) EMBO J. 2023 Jul 17;42(14):e112259. (PMID: 37272165) Nat Med. 2007 Aug;13(8):975-80. (PMID: 17676051) J Invest Dermatol. 2019 Dec;139(12):2437-2446.e1. (PMID: 31207232) J Dermatol. 2016 Nov;43(11):1283-1292. (PMID: 27075216) J Invest Dermatol. 2024 Jan;144(1):33-42.e2. (PMID: 37437773) Inflammopharmacology. 2025 Apr;33(4):1935-1947. (PMID: 39821787) Dermatol Ther. 2022 Nov;35(11):e15848. (PMID: 36175135) J Invest Dermatol. 2021 Apr;141(4):800-809. (PMID: 32941918) Inflamm Res. 2025 Nov 26;74(1):174. (PMID: 41296102) J Clin Invest. 2017 Nov 1;127(11):4031-4041. (PMID: 28945199) J Am Acad Dermatol. 2024 Sep;91(3):466-473. (PMID: 38878041) J Invest Dermatol. 2011 Mar;131(3):688-97. (PMID: 21107351) J Invest Dermatol. 2021 Dec;141(12):2885-2894.e5. (PMID: 33745908) Free Radic Biol Med. 2026 Feb 16;244:422-434. (PMID: 41421415) Skin Health Dis. 2026 Feb 06;6(2):138-145. (PMID: 41923975) Nat Commun. 2024 Oct 9;15(1):8737. (PMID: 39384741) J Inflamm Res. 2024 Jul 09;17:4443-4452. (PMID: 39006492) Nat Rev Drug Discov. 2023 Aug;22(8):662-680. (PMID: 37443275) Int Immunopharmacol. 2023 May;118:110057. (PMID: 36989903) Indian J Pathol Microbiol. 2026 Apr 1;69(2):289-294. (PMID: 42085043) J Invest Dermatol. 2014 Nov;134(11):2728-2736. (PMID: 24844861) Nat Rev Immunol. 2020 Jun;20(6):375-388. (PMID: 32132681) Nat Rev Immunol. 2022 May;22(5):283-293. (PMID: 34480118) J Allergy Clin Immunol. 2025 Apr;155(4):1264-1275. (PMID: 39522654) Nat Commun. 2019 Dec 11;10(1):5670. (PMID: 31827093) Int J Dermatol. 2025 Dec;64 Suppl 2:42-51. (PMID: 41404901) Arthritis Rheumatol. 2015 Jan;67(1):86-95. (PMID: 25199798) North Clin Istanb. 2024 Jan 31;11(1):27-37. (PMID: 38357320) Am J Clin Dermatol. 2024 Nov;25(6):997-1008. (PMID: 39283586) J Immunol. 2014 Apr 1;192(7):3111-20. (PMID: 24610014) PLoS One. 2012;7(2):e30308. (PMID: 22348003) Ann Dermatol. 2017 Oct;29(5):543-547. (PMID: 28966509) Ewha Med J. 2025 Jan;48(1):e78. (PMID: 40704211) Int J Mol Sci. 2023 Feb 25;24(5):. (PMID: 36901987) J Dermatolog Treat. 2026 Dec;37(1):2636417. (PMID: 41814992) Nat Commun. 2024 Aug 23;15(1):7265. (PMID: 39179539) JAMA Dermatol. 2025 May 01;161(5):499-507. (PMID: 40042869) JAMA Dermatol. 2020 Feb 1;156(2):131-143. (PMID: 31876900) Cell Stem Cell. 2021 Oct 7;28(10):1758-1774.e8. (PMID: 34320411) |
| Contributed Indexing: | Keywords: disease modification; epithelial memory; inflammatory memory; relapse threshold; rosacea; tissue-resident memory T cells; trained immunity |
| Entry Date(s): | Date Created: 20261015 Date Completed: 20261015 Latest Revision: 20261016 |
| Update Code: | 20261017 |
| PubMed Central ID: | PMC13662847 |
| DOI: | 10.3389/fimmu.2026.1962766 |
| PMID: | 42877634 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1962766 |